GE Healthcare and BAC Expand Collaboration
BAC BV (Naarden, The Netherlands) has announced the expansion of its collaboration with GE Healthcare with the addition of new bioprocess affinity chromatography media to GE Healthcare’s range of custom-designed media.
BAC BV (Naarden, The Netherlands) has announced the expansion of its collaboration with GE Healthcare with the addition of new bioprocess affinity chromatography media to GE Healthcare’s range of custom-designed media. The latest addition to the range is an affinity media for the specific purification of antibody fragments containing the kappa light chain, based on BAC’s CaptureSelect Fab Kappa ligand. The new media have been developed as part of GE Healthcare’s Custom-Design Media (CDM) program.
BAC’s CaptureSelect ligands offer enhanced stability and specificity compared to traditional affinity ligands, thus offering the potential to reduce lengthy purification processes to a single step, with higher throughput, and reduced costs. The Fab Kappa ligand provides a unique affinity solution for an antibody subset that has previously been extremely difficult to purify.
BAC release
The Solution Lies with SOLBIOTE™: Achieving Sustainability, a Growing Focus in Biopharma
October 28th 2024The nexus between biopharmaceuticals and sustainability is seemingly far apart, however, it is increasingly recognized as an inevitable challenge. It is encouraged to take a sustainable approach to reducing the environmental impact of the production and supply of medicines while improving people's health; delivering the well-being of people and the planet. Yosuke Shimojo (Technical Value Support Section Manager, Nagase Viita) will unveil how SOLBIOTE™, a portfolio of injectable-grade saccharide excipients, would be a key for the biopharmaceutical development and achieving sustainability for a better future of the industry.
